CN102204933B - 一种抗肿瘤生物制品的制备方法 - Google Patents
一种抗肿瘤生物制品的制备方法 Download PDFInfo
- Publication number
- CN102204933B CN102204933B CN201110074364A CN201110074364A CN102204933B CN 102204933 B CN102204933 B CN 102204933B CN 201110074364 A CN201110074364 A CN 201110074364A CN 201110074364 A CN201110074364 A CN 201110074364A CN 102204933 B CN102204933 B CN 102204933B
- Authority
- CN
- China
- Prior art keywords
- allantoic fluid
- chicken embryo
- ndv
- preparation
- purifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000012530 fluid Substances 0.000 claims abstract description 85
- 241000287828 Gallus gallus Species 0.000 claims abstract description 43
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 43
- 241000700605 Viruses Species 0.000 claims abstract description 16
- 238000000108 ultra-filtration Methods 0.000 claims description 38
- 238000005336 cracking Methods 0.000 claims description 31
- 238000011081 inoculation Methods 0.000 claims description 28
- 239000012528 membrane Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 230000003067 hemagglutinative effect Effects 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 206010011732 Cyst Diseases 0.000 claims description 9
- 108010000912 Egg Proteins Proteins 0.000 claims description 9
- 102000002322 Egg Proteins Human genes 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000031513 cyst Diseases 0.000 claims description 9
- 210000003278 egg shell Anatomy 0.000 claims description 9
- 230000004720 fertilization Effects 0.000 claims description 9
- 238000005227 gel permeation chromatography Methods 0.000 claims description 9
- 230000012447 hatching Effects 0.000 claims description 9
- 230000002101 lytic effect Effects 0.000 claims description 9
- 239000012188 paraffin wax Substances 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 239000010902 straw Substances 0.000 claims description 9
- 239000005723 virus inoculator Substances 0.000 claims description 9
- 241000711404 Avian avulavirus 1 Species 0.000 abstract description 38
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 108010058846 Ovalbumin Proteins 0.000 abstract description 3
- 229940092253 ovalbumin Drugs 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 230000035931 haemagglutination Effects 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
组别 | 药品 | 小鼠(只) | 用药方案 | 用药次数 | 抑瘤率(%) |
1 | 生理盐水 | 8 | 1次/天 | 7次 | |
2 | 环磷酰胺 | 8 | 1次/天 | 7次 | 90.1 |
3※ | 实施例1所述制品 | 8 | 1次/天 | 7次 | 88.5 |
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110074364A CN102204933B (zh) | 2011-03-25 | 2011-03-25 | 一种抗肿瘤生物制品的制备方法 |
PCT/CN2011/077835 WO2012129873A2 (zh) | 2011-03-25 | 2011-07-31 | 一种抗肿瘤生物制品的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110074364A CN102204933B (zh) | 2011-03-25 | 2011-03-25 | 一种抗肿瘤生物制品的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102204933A CN102204933A (zh) | 2011-10-05 |
CN102204933B true CN102204933B (zh) | 2012-10-10 |
Family
ID=44694176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110074364A Expired - Fee Related CN102204933B (zh) | 2011-03-25 | 2011-03-25 | 一种抗肿瘤生物制品的制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102204933B (zh) |
WO (1) | WO2012129873A2 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103566366A (zh) * | 2013-09-23 | 2014-02-12 | 天津瑞普生物技术股份有限公司 | 一种肉鸡用新城疫水包油包水型灭活疫苗制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1138485A (zh) * | 1995-06-16 | 1996-12-25 | 秦民德 | 新城疫病毒的用途和制备方法 |
GB2451428A (en) * | 2007-07-25 | 2009-02-04 | Pliva Hrvatska D O O | Process for preparing an in ovo combination viral vaccine |
CN101396557A (zh) * | 2007-09-27 | 2009-04-01 | 上海生物制品研究所 | 一种麻疹腮腺炎风疹联合减毒活疫苗的制备方法 |
CN101633912A (zh) * | 2008-07-22 | 2010-01-27 | 大连雅立峰生物制药有限公司 | 适合于大规模生产人用禽流感疫苗的裂解方法 |
CN101508977B (zh) * | 2009-01-04 | 2010-09-29 | 山东省农业科学院畜牧兽医研究所 | 一种鸡源h9n2禽流感病毒毒株的分离鉴定和纯化方法及其应用 |
CN101850110A (zh) * | 2009-03-30 | 2010-10-06 | 天津泽世德生物医药有限公司 | 一种新的药物组合物及制备方法 |
-
2011
- 2011-03-25 CN CN201110074364A patent/CN102204933B/zh not_active Expired - Fee Related
- 2011-07-31 WO PCT/CN2011/077835 patent/WO2012129873A2/zh active Application Filing
Non-Patent Citations (2)
Title |
---|
郝景波等.重组新城疫病毒Anhinga株与TRAIL蛋白协同杀伤肿瘤细胞.《中国生物化学与分子生物学报》.2011,第27卷(第1期),32-39. |
重组新城疫病毒Anhinga株与TRAIL蛋白协同杀伤肿瘤细胞;郝景波等;《中国生物化学与分子生物学报》;20110131;第27卷(第1期);32-39 * |
Also Published As
Publication number | Publication date |
---|---|
CN102204933A (zh) | 2011-10-05 |
WO2012129873A3 (zh) | 2012-11-22 |
WO2012129873A2 (zh) | 2012-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102120768B (zh) | 利用生物反应器生产治疗性犬细小病毒单克隆抗体的方法 | |
CN102166356A (zh) | α-甘露聚糖肽作为疫苗佐剂的应用及基于该应用制备的疫苗制剂 | |
CN103585626B (zh) | 一种鸡新城疫、法氏囊病二联复合灭活疫苗的制备方法 | |
CN104231068A (zh) | 人白细胞介素ii突变体及其应用 | |
CN106222141B (zh) | Nk细胞培养液和细胞培养方法 | |
CN107904215A (zh) | 一种禽流感病毒的全悬浮培养方法 | |
CN103275912B (zh) | 肠出血性大肠杆菌O157:H7多价fliC-hcpA-tir-eae重组菌及疫苗 | |
CN102204933B (zh) | 一种抗肿瘤生物制品的制备方法 | |
CN103599130A (zh) | 抗鸡新城疫病毒特异性转移因子及口服液制备方法和用途 | |
CN101721427B (zh) | 一种鸡新城疫特异性转移因子的制备方法 | |
CN103232545A (zh) | 一种重组猪干扰素α1-Fc融合蛋白及其编码基因和表达方法 | |
CN102205118B (zh) | 一种生物制品及其制备方法 | |
CN103232544B (zh) | 一种重组猪干扰素γ-Fc融合蛋白及其编码基因和表达方法 | |
CN102716481A (zh) | 一种罗非鱼用口服疫苗免疫佐剂及其应用 | |
CN102212524A (zh) | 作为牛和猪免疫调节剂及疫苗佐剂的脱氧寡核苷酸 | |
CN104208675A (zh) | 一种抗鸡病毒性疾病的混合冻干粉及其制备方法 | |
CN102813920A (zh) | 一种疫苗佐剂 | |
CN106754701A (zh) | 一种nk细胞体外诱导、扩增方法 | |
JPS6011890B2 (ja) | ツモアネクロシスフアクタ−の製造方法 | |
CN102154418B (zh) | 一种动物干扰素的制备方法 | |
CN104208681B (zh) | 一种抗鸭病毒性疾病的混合冻干粉及其制备方法 | |
CN102151290B (zh) | 一种禽用特异性转移因子的制备方法 | |
CN107670032A (zh) | 家禽油乳剂灭活疫苗佐剂及其相应疫苗的制备方法 | |
CN101899446B (zh) | 一种重组鸭α -干扰素的制备方法 | |
CN101260143A (zh) | 高效生产犬白细胞干扰素的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GU CHANGQING Free format text: FORMER OWNER: TIANJIN JIMINGSHENG BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20130513 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300384 NANKAI, TIANJIN TO: 300050 HEPING, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130513 Address after: 300050 Tianjin City District 55 Mu South Road No. 3 Building 3 No. 503 Patentee after: Gu Changqing Address before: 300384 Tianjin Lanyuan Nankai District Huayuan Industrial Zone Road No. 5 Building No. four, block B 303 Patentee before: Tianjin Jimingsheng Biological Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121010 Termination date: 20170325 |
|
CF01 | Termination of patent right due to non-payment of annual fee |